PROM1 and neoplasm: The expression of CD133 in CRC has already been reported to be involved with drug resistance and disease recurrence and also associated with lower patients survival.15, 32, 33, 38 However, our follow‐up study showed higher recurrence rate in group with CD133 enrichment in distal margin compared to CD133 tumour enriched group (Table 1).